Colin R. Lindsay
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor.
Journal: JCO precision oncology
Published: November 14, 2025
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.
Journal: Cancer discovery
Published: September 23, 2025
Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland.
Journal: Journal of medical economics
Published: July 21, 2025
Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 02, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 25, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 25, 2025
The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.
Journal: Cell death & disease
Published: March 20, 2025
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.
Journal: Nature medicine
Published: January 27, 2025
Prevalence and breakdown of KRAS driver mutations in a large UK non-small cell lung cancer cohort.
Journal: Journal of clinical pathology
Published: November 27, 2024
First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 05, 2024
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 07, 2024
Last Updated: 09/26/2026